A one-year study on the pharmacodynamic profile of interferon-beta1a in MS.
Interferon (IFN)-beta1a induction of neopterin and beta2-microglobulin (beta2-MG) were evaluated over 1 year in patients with MS. Neopterin and beta2-MG levels peaked 24 to 48 hours after weekly injections of IFNbeta1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNgamma expression and macrophage activation during IFNbeta-1a treatment. Predose levels of beta2-MG increased, the significance of which is as yet unclear.
Bagnato
F
F
Department of Neurological Sciences, University La Sapienza, Rome, Italy. francesca.bagnato@uniroma1.it
Pozzilli
C
C
Scagnolari
C
C
Bellomi
F
F
Pasqualetti
P
P
Gasperini
C
C
Millefiorini
E
E
Galgani
S
S
Spadaro
M
M
Antonelli
G
G
D000328:Adult; D000704:Analysis of Variance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D016014:Linear Models; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000188:drug therapy*; D019798:Neopterin / Q000097:blood*; D012008:Recurrence; D013995:Time; D001613:beta 2-Microglobulin / Q000097:blood*
D001613:beta 2-Microglobulin; D019798:Neopterin; D016899:Interferon-beta; D000068556:Interferon beta-1a